195 related articles for article (PubMed ID: 20030521)
1. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.
Malyszko J; Malyszko JS; Kozminski P; Mysliwiec M
Ren Fail; 2009; 31(10):876-83. PubMed ID: 20030521
[TBL] [Abstract][Full Text] [Related]
2. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Am J Hematol; 2006 Nov; 81(11):832-7. PubMed ID: 16929540
[TBL] [Abstract][Full Text] [Related]
3. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transplant Proc; 2009 Oct; 41(8):3056-9. PubMed ID: 19857675
[TBL] [Abstract][Full Text] [Related]
4. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
[TBL] [Abstract][Full Text] [Related]
5. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
Malyszko J; Malyszko JS; Mysliwiec M
Kidney Blood Press Res; 2009; 32(4):235-8. PubMed ID: 19713706
[TBL] [Abstract][Full Text] [Related]
6. Is hepcidin a link between anemia, inflammation and liver function in hemodialyzed patients?
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Mysliwiec M
Am J Nephrol; 2005; 25(6):586-90. PubMed ID: 16254410
[TBL] [Abstract][Full Text] [Related]
7. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
[TBL] [Abstract][Full Text] [Related]
8. Hepcidin, an acute-phase protein and a marker of inflammation in kidney transplant recipients with and without coronary artery disease.
Malyszko J; Malyszko JS; Pawlak K; Mysliwiec M
Transplant Proc; 2006 Nov; 38(9):2895-8. PubMed ID: 17112858
[TBL] [Abstract][Full Text] [Related]
9. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
10. Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients.
Lin TJ; Liao LY; Chou JM; Liu SO; Wang CK
Hepatogastroenterology; 2009; 56(93):1146-51. PubMed ID: 19760959
[TBL] [Abstract][Full Text] [Related]
11. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients.
Arabul M; Gullulu M; Yilmaz Y; Eren MA; Baran B; Gul CB; Kocamaz G; Dilek K
Med Sci Monit; 2009 Nov; 15(11):CR583-7. PubMed ID: 19865058
[TBL] [Abstract][Full Text] [Related]
12. Serum pro-hepcidin as an indicator of iron status in dialysis patients.
Tsuchihashi D; Abe T; Komaba H; Fujii H; Hamada Y; Nii-Kono T; Tanaka M; Fukagawa M
Ther Apher Dial; 2008 Jun; 12(3):226-31. PubMed ID: 18503700
[TBL] [Abstract][Full Text] [Related]
13. Does hepcidin affect erythropoiesis in hemodialysis patients?
Eleftheriadis T; Kartsios C; Liakopoulos V; Antoniadi G; Ditsa M; Papadopoulos C; Anifandis G; Skirta A; Markala D; Stefanidis I
Acta Haematol; 2006; 116(4):238-44. PubMed ID: 17119323
[TBL] [Abstract][Full Text] [Related]
14. Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI).
Sasu BJ; Li H; Rose MJ; Arvedson TL; Doellgast G; Molineux G
Blood Cells Mol Dis; 2010 Oct; 45(3):238-45. PubMed ID: 20800515
[TBL] [Abstract][Full Text] [Related]
15. Reproducibility of and correspondence among different hepcidin forms in blood and urine and their relationships to iron status in healthy, male Guatemalan volunteers observed over 9 weeks.
Schuemann K; Solomons NW; Laarakkers CM; Romero-Abal ME; Kroll S; Weiss G; Swinkels DW
Ann Nutr Metab; 2011; 58(2):158-66. PubMed ID: 21654163
[TBL] [Abstract][Full Text] [Related]
16. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease.
Arabul M; Gullulu M; Yilmaz Y; Akdag I; Kahvecioglu S; Eren MA; Dilek K
Clin Biochem; 2008 Sep; 41(13):1055-8. PubMed ID: 18571502
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil gelatinase-associated lipocalin in dialyzed patients is related to residual renal function, type of renal replacement therapy and inflammation.
Malyszko J; Malyszko JS; Koc-Zorawska E; Kozminski P; Mysliwiec M
Kidney Blood Press Res; 2009; 32(6):464-9. PubMed ID: 20068352
[TBL] [Abstract][Full Text] [Related]
18. [Pro-hepcidin, its relation with indicators of iron metabolism and of inflammation in patients hemodialyzed treated or not with recombinant erythropoietin].
Barrios Y; Espinoza M; Barón MA
Nutr Hosp; 2010; 25(4):555-60. PubMed ID: 20694291
[TBL] [Abstract][Full Text] [Related]
19. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
20. Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M.
Beirão I; Almeida S; Swinkels D; Costa PM; Moreira L; Fonseca I; Freitas C; Cabrita A; Porto G
Blood Cells Mol Dis; 2008; 41(2):175-8. PubMed ID: 18544472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
